Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00908752 · ClinicalTrials.gov registry record · Phase 3
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 734
- Enrollment target
NCT00908752 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 734 participants.
The verdict
NCT00908752, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 734 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the Overall Survival (OS) of HCC patients who receive brivanib as adjuvant treatments to TACE therapy, with the OS of HCC patients who receive matched placebo with TACE therapy.
Interventions
- DRUG Brivanib
- OTHER Brivanib Placebo
- PROCEDURE TACE Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 734 participants |
| Start Date | 2009-07-20 |
| Est. Completion | 2018-01-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00908752
The ClinicalTrials.gov registry entry for NCT00908752 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 734 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Brivanib is the first listed.
NCT00908752 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00908752 about?
NCT00908752 is a clinical study titled "Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC". The purpose of this study is to compare the Overall Survival (OS) of HCC patients who receive brivanib as adjuvant treatments to TACE therapy, with the OS of HCC patients who receive matched placebo with TACE therapy.
What is the current status of trial NCT00908752?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 734 participants. The study started on 2009-07-20. Estimated completion is 2018-01-26.
What interventions are being tested in trial NCT00908752?
The interventions under investigation include: Brivanib (DRUG), Brivanib Placebo (OTHER), TACE Therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00908752?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.